CompanyGraph
What stands out
- Earnings significantly exceed cash generation
- Dividend several times the last twelve months' earnings
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 0.75×, lower than 95% of its Biotechnology peers (median 2.97×)
- FinancialsAltman Z-Score 6.32: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
2.72%
Annual Rate
CNY 0.80Paid annual
Payout Ratio
400.0%High
Payback Period
36.9 yr
Last Ex-Dividend
Jul 9, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.74BCNY556.75M · vs all stocks (USD)
Trailing P/E
151.45xvs Biotechnology peers
Revenue (TTM)
407.16MCNY60.55M · vs all stocks (USD)
Profit Margin
6.15%vs Biotechnology peers
Beta
0.5890xvs all stocks
52-Week Change
-29.71%vs all stocks
Market Capitalization
3.74BCNY556.75M · vs all stocks (USD)
Enterprise Value
1.94BCNY288.02M · vs all stocks (USD)
Trailing P/E
151.45xvs Biotechnology peers
Price to Sales (TTM)
9.45xvs Biotechnology peers
Price to Book (MRQ)
0.7474xvs Biotechnology peers
Enterprise to Revenue
4.76xvs Biotechnology peers
Gross Margin
40.80%vs Biotechnology peers
Profit Margin
6.15%vs Biotechnology peers
Operating Margin
-15.55%vs Biotechnology peers
Return on Assets (TTM)
-0.46%vs Biotechnology peers
Return on Equity (TTM)
0.47%vs Biotechnology peers
Revenue (TTM)
407.16MCNY60.55M · vs all stocks (USD)
Revenue per Share (TTM)
3.20CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-38.20%vs Biotechnology peers
Gross Profit (TTM)
163.94MCNY24.38M · vs all stocks (USD)
EBITDA (TTM)
109.33MCNY16.26M · vs all stocks (USD)
Net Income (TTM)
25.03MCNY3.72M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-48.19%vs Biotechnology peers
Operating Cash Flow (TTM)
-1.38MCNY-205.68K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.8000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.72%vs all stocks
Payout Ratio
400.00%vs Biotechnology peers
Minority Interest (Equity)
-4.02MCNYFY2025 · Dec 31, 2025Revenue
451.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
259.45MCNYFY2025 · Dec 31, 2025Gross Profit
191.80MCNYFY2025 · Dec 31, 2025Operating Income
-15.30MCNY-2.28M · vs all stocks (USD)
Pre-tax Income
74.87MCNYFY2025 · Dec 31, 2025Income Tax Expense
5.66MCNYFY2025 · Dec 31, 2025Net Income
69.21MCNYFY2025 · Dec 31, 2025EBIT
75.15MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
109.33MCNYFY2025 · Dec 31, 2025Research & Development
78.65MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
46.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
28.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
275.57KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
126.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
126.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
69.21MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
211.52KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
138.12MCNYFY2025 · Dec 31, 2025Free Cash Flow
42.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
420.10MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
69.21MCNYFY2025 · Dec 31, 2025Other Non-cash Items
40.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
20.13MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.51MCNYFY2025 · Dec 31, 2025Capital Expenditures
-95.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.32BCNYFY2025 · Dec 31, 2025Sale of Investments
10.69BCNYFY2025 · Dec 31, 2025Other Investing Activity
-157.90MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
117.89MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-280.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-101.67MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-106.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
127.08MSharesUpdated Aug 21, 2026Float Shares
32.97MSharesUpdated Aug 21, 2026% Held by Insiders
75.15%vs all stocks
% Held by Institutions
4.27%vs all stocks
Total Cash (MRQ)
1.90BCNY282.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
14.95CNYUpdated Aug 21, 2026Total Debt (MRQ)
145.53MCNY21.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0283xvs Biotechnology peers
Current Ratio (MRQ)
8.87xvs Biotechnology peers
Book Value per Share (MRQ)
40.53CNYUpdated Aug 21, 2026Total Assets
5.68BCNY844.16M · vs all stocks (USD)
Total Current Assets
4.59BCNYFY2025 · Dec 31, 2025Total Liabilities
515.98MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.08BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
78.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
437.14MCNYFY2025 · Dec 31, 2025Cash
423.52MCNYFY2025 · Dec 31, 2025Cash Equivalents
144.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
568.27MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.31BCNYFY2025 · Dec 31, 2025Accounts Receivable
187.06MCNYFY2025 · Dec 31, 2025Inventory
133.34MCNYFY2025 · Dec 31, 2025Accounts Payable
382.91MCNYFY2025 · Dec 31, 2025Short-term Debt
3.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
539.03KCNYFY2025 · Dec 31, 2025Long-term Debt
2.11MCNYFY2025 · Dec 31, 2025Common Stock (Book)
127.08MCNYFY2025 · Dec 31, 2025Retained Earnings
3.92BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.16BCNY767.43M · vs all stocks (USD)
52-Week Low
26.88CNYUpdated Aug 21, 202652-Week High
45.00CNYUpdated Aug 21, 202652-Week Change
-29.71%vs all stocks
Beta
0.5890xvs all stocks
50-Day MA
29.43CNYUpdated Aug 21, 2026200-Day MA
36.35CNYUpdated Aug 21, 2026Avg 10-Day Volume
789.05KSharesUpdated Aug 21, 2026Avg 30-Day Volume
828.56KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.2000CNYUpdated Aug 21, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.75×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.75Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 3,722,457.266Operating Cash Flow (USD, TTM): -205,675.596
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 4.00Dividend per Share: 0.80Earnings per Share: 0.20
High gross margins eroded by operating costsNotable
Gross Margin: 0.41Profit Margin: 0.06
Financial Health
Altman Z-Score 6.32: safe zoneNotable
Altman Z-Score: 6.32
High earnings qualityNotable
Earnings Quality Score: 0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Luyang Energy-saving Materials Co., Ltd.
5 interpretationsHigh Retained Earnings With Profitability And EquityClose Below 40W SMA With ProfitabilityRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Shanghai Flyco Electrical Co., Ltd.
5 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Zhubo Design Co. Ltd.
5 interpretationsCash-Flow Ratios ElevatedDebt Falling While Share Count RisesClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity